Alaunos Therapeutics, Inc. (TCRT) · Oct 9, 2026 · Delisting
Delisting notice — $2.5M minimum equity rule; hearing required to stay delisting
Alaunos received a Nasdaq delisting notice after failing the equity rule and is turning to a hearing and uncommitted strategic alternatives.
Alaunos is a preclinical-stage company focused on obesity and metabolic-disorder therapies after winding down its earlier TCR-T cancer program, with strategic alternatives already part of its survival plan.
Nasdaq has escalated the problem from deficiency to formal delisting risk. The April 9, 2026 disclosure established that Alaunos was below Nasdaq’s $2.5 million stockholders’ equity requirement; this filing says the company has now received a written notice making its securities subject to delisting unless it requests a hearing. 〔0〕
The hearing buys time, not compliance. Alaunos plans to request a hearing, which temporarily stays further suspension or delisting action, but the filing offers no completed financing, transaction, or other identified remedy that restores the required equity level. 〔1〕
The proposed solution remains highly speculative. The company says it is working with a financial advisor and evaluating transactions to strengthen its balance sheet, but no definitive agreement exists and the filing expressly leaves open whether a suitable transaction can be found or completed. 〔2〕
Bottom line: This is a meaningful deterioration from a known equity deficiency to an active delisting process. The hearing preserves Nasdaq access temporarily, but the business still needs an actual capital or strategic transaction to solve the underlying problem.
Nasdaq hearing request and Hearings Panel decision
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!